Cited by 87Alzheimer's disease research and treatmentsNeuroscience and Neuropharmacology ResearchDementia and Cognitive Impairment Research

APP/PS1KI bigenic mice develop early synaptic deficits and hippocampus atrophy

Open access
Breyhan, Henning, Wirths, Oliver, Duan, Kailai, Marcello, Andrea, Rettig, Jens, Bayer, Thomas A.·2009·Acta Neuropathologica

Abstract

Abeta accumulation has an important function in the etiology of Alzheimer's disease (AD) with its typical clinical symptoms, like memory impairment and changes in personality. However, the mode of this toxic activity is still a matter of scientific debate. We used the APP/PS1KI mouse model for AD, because it is the only model so far which develops 50% hippocampal CA1 neuron loss at the age of 1 year. Previously, we have shown that this model develops severe learning deficits occurring much earlier at the age of 6 months. This observation prompted us to study the anatomical and cellular basis at this time point in more detail. In the current report, we observed that at 6 months of age there is already a 33% CA1 neuron loss and an 18% atrophy of the hippocampus, together with a drastic reduction of long-term potentiation and disrupted paired pulse facilitation. Interestingly, at 4 months of age, there was no long-term potentiation deficit in CA1. This was accompanied by reduced levels of pre- and post-synaptic markers. We also observed that intraneuronal and total amount of different Abeta peptides including N-modified, fibrillar and oligomeric Abeta species increased and coincided well with CA1 neuron loss. Overall, these data provide the basis for the observed robust working memory deficits in this mouse model for AD at 6 months of age.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00401-009-0539-7

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In APP/PS1KI mice, a loss of ~30% of CA1 neurons was demonstrated already in 6-month-old animals, coinciding with strong intraneuronal accumulation of full-length, N-terminally truncated, pyroglutamate-modified, and oligomeric Aβ species.

    “More thorough follow-up studies demonstrated a loss of ~30% of CA1 neurons already in 6-month-old animals, coinciding with a strong intraneuronal accumulation of full-length, but also N-terminally truncated, pyroglutamate-modified, as well as oligomeric Aβ species [82].”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Breyhan, H., Wirths, O., Duan, K., Marcello, A., Rettig, J., & Bayer, T. A.
Affiliations
  • University of Göttingen (DE)
  • Saarland University (DE)
Corresponding author
Bayer, Thomas A.
Venue
Acta Neuropathologica
Published
2009-04-23
Volume
117
Issue
6
Pages
677-685
ISSN
  • 0001-6322 (ISSN-L)
  • 1432-0533
OpenAlex
W1979170530
Cited by
87
References
48
Citations by year
2026: 1 · 2025: 1 · 2023: 3 · 2022: 3 · 2021: 4 · 2020: 2 · 2019: 5 · 2018: 8 · 2017: 3 · 2016: 7 · 2015: 8 · 2014: 5 · 2013: 10 · 2012: 6
FWCI
5.96
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • Acta Neuropathologica (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • GoeScholar The Publication Server of the Georg-August-Universität Göttingen (Georg-August-Universität Göttingen) (submittedVersion, cc-by)
Funders
  • Alzheimer Forschung Initiative
  • European Commission (MEST-CT-2005-020013)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords
Alzheimer's disease, amyloid-beta, hippocampal atrophy, synaptic deficits, long-term potentiation, paired-pulse facilitation, intraneuronal amyloid-beta, amyloid-beta oligomers, working memory deficits, mouse model
MeSH terms
Alzheimer Disease, Animals, Atrophy, Disease Models, Animal, Hippocampus, Humans, Mice, Transgenic, Neurons, Peptides, Receptors, Cell Surface, Synapses, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Cell Death, Long-Term Potentiation, Excitatory Postsynaptic Potentials, Mice, Presenilin-1, Protease Nexins, In Vitro Techniques

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review